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Ichthyosis prematurity syndrome (IPS) is an autosomal-recessive disorder characterized by premature birth and neonatal asphyxia, fol-
lowed by a lifelong nonscaly ichthyosis with atopicmanifestations. Here we show that the gene encoding the fatty acid transport protein
4 (FATP4) is mutated in individuals with IPS. Fibroblasts derived from a patient with IPS show reduced activity of very long-chain fatty
acids (VLCFA)-CoA synthetase and a speciﬁc reduction in the incorporation of VLCFA into cellular lipids. The human phenotype is
consistent with Fatp4 deﬁciency in mice that is characterized by a severe skin phenotype, a defective permeability barrier function,
and perturbed VLCFA metabolism. Our results further emphasize the importance of fatty acid metabolism for normal epidermal barrier
function illustrated by deﬁciency of a member in the FATP family of proteins.Autosomal-recessive congenital ichthyosis (ARCI) is a
heterogeneous group of keratinization disorders charac-
terized by a defective barrier function.1,2 ARCI is associated
withmutations in genes of importance for the intercellular
lipid layer or corniﬁed cell envelope.3 To date, seven genes
are known to cause ARCI in humans: TGM1 (MIM
*190195),4,5 ABCA12 (MIM *607800),6,7 the two lipoxyge-
nase genes ALOXE3 (MIM *607206) and ALOX12B (MIM
*603741),8 CGI-58 (ABHD5 [MIM *604780]),9,10 Ichthyin
(NIPAL4 [MIM *609383]),11,12 and CYP4F22 (MIM
*611495).13 Furthermore, linkage analysis has established
at least three additional ARCI loci on chromosomes
9q33.3-q34.13,14,15 12p11.2-q13,16 and 19p13.1-p13.2
(MIM %604781).17 The 9q33.3-q34.13 loci is associated
with the ichthyosis prematurity syndrome (IPS [MIM
%608649]) or ichthyosis congenita type IV.18 Key features
in IPS are complications in the second trimester of preg-
nancy resulting from polyhydramnion, with premature
birth of a childwith thick caseous desquamating epidermis,
respiratory complications, and transient eosinophilia. After
recovery during the ﬁrst months of life, the symptoms are
relatively benign and the patients suffer from a lifelong
nonscaly ichthyosis with atopic manifestations (Figures
1A–1C). Ultrastructural analyses reveal membrane aggrega-
tions in the upper epidermal layers, and histological anal-
ysis of the skin shows a thickening of the epidermis (Figures
1D–1F). The prevalence of IPS is relatively high in a region
across mid-Scandinavia, suggesting a founder effect in this
population with one predominant ancestral mutation.14
We performed a homozygosity scan on a consanguineous
family of North African origin comprising several individ-
uals with IPS. Affected family members were found homo-
zygous for a 76 kb genomic region on chromosome 9p
that coincides with the IPS locus in the Scandinavian fami-
lies. The region spans four genes, including the FATP4248 The American Journal of Human Genetics 85, 248–253, August 1(SLC27A4 [MIM *604194]) gene encoding a member of
the fatty acid transport protein (FATPs or solute carrier
family 27, SLC27) family. The FATP4 gene consists of 13
exons encoding a peptide of 643 residues with a predicted
size of 72 kDa. FATP4 is highly conserved among widely
divergent species and contains an N-terminal transmem-
brane (TM) region, an ER localization signal (ERx), and an
AMP-binding domain.19 The FATP family comprises trans-
membrane proteins of importance for the uptake of exoge-
nous fatty acids into cells.20 Members of this family also
function as acyl-CoA synthetases with speciﬁcity for very
long-chain fatty acids (VLCFA) or bile acids.21 Several
FATPs, including FATP4, are present in the epidermis, and
animal studies suggest an important role of these trans-
porters for skin barrier function.22 Fatp4/mice die either
in utero23 or in the neonatal period,24,25 showing a thick-
ened, malformed skin with ineffective barrier properties
and severe breathing difﬁculties secondary to the tight
skin. The critical role of FATP4 is demonstrated by rescuing
the lethal phenotype in Fatp4/ mice by keratinocyte-
speciﬁc transgenic expression of FATP4, resulting in viable
mice with only a mild skin phenotype.26
Sequence analysis of FATP4 in affected members from
the North African family, 1 Middle Eastern family, and
18 IPS families of Scandinavian origin revealed 7 different
mutations (Figure 2A). The study complies with the decla-
ration of Helsinki and is performed according to a protocol
approved by the regional ethical committee at CEA and at
the Universities of Uppsala and Bab El Oued. Sequencing
of 120 healthy control individuals failed to reveal any of
the described mutations (N ¼ 240; >80% power with
a polymorphism frequency of 0.01).27 All Scandinavian
patients were found homozygous or compound heterozy-
gous for a nonsense mutation (c.504c>a [p.C168X]) in
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A founder effect was conﬁrmed by the presence of a
conserved 786 kb region spanning the mutation (Figure S1
available online). The North African patient, daughter to
consanguineous parents, was homozygous for an exon 5
acceptor splice site mutation (c.716-1g>a) predicting
Figure 1. Key Features of IPS
(A and B) Premature birth of a child with
IPS showing thick, caseous, desquamating
skin, particularly of the head, and respira-
tory complications.
(C)Later, thephenotypebecomesmildwith
a cobblestone-like surface. The pictures
are published with permission from the
parents.
(D) Electron microscopic analysis of super-
ﬁcial epidermis from an IPS patient
showing accumulation of curved multila-
mellar membranes in stratum granulosum
(37,500); the inset shows the region at
a higher magniﬁcation (330,000).
(E and F) Histological analysis by hematox-
ylin and eosin (H&E) staining of skin from
an IPS patient (E) showing thickening of
the epidermis when compared to normal
control (F).
a truncated protein (Table S1). The
mutations segregated with the disease
in each family, with parents being
heterozygous carriers for the respec-
tive mutations based on haplotype
analysis. FATPs are required for
cellular fatty acid uptake and for
the activation of fatty acids. The
AMP-binding domain (aa 103–536)
of FATP4 comprise two distinct
motifs: the ATP/AMP motif, involved
in ATP binding and adenylate formation common to all
adenylate-forming enzymes (aa 243–345), as well as the
FATP/VLACS motif of the FATP and very long-chain acyl-
CoA synthetase (VLACS) protein families (aa 500–551),
involved in fatty acid binding. We identiﬁed two missenseFigure 2. Overview of FATP4 Mutations and Western Analysis
(A) Positions of FATP4 mutations in IPS patients with frequencies in the Scandinavian patients.
(B) Schematic overview of FATP4 functional domains; the N-terminal transmembrane region (TM), the ER localization signal (ERx; aa
47–102), and the AMP binding domain (gray; aa 103–536) containing the ATP/AMPmotif involved in ATP binding and adenylate forma-
tion (ATP/AMP; aa 243–345) and the conserved FATPmotif of importance for fatty acid binding (FATP; aa 500–551). The numbers below
the bar correspond to residues mutated in IPS.
(C) Protein blot showing FATP4 protein expression in a control individual and absent expression in a patient homozygous for p.C168X
(MW: FATP4 72 kDa, GAPDH 37 kDa) with a monoclonal FATP4 antibody (Abnova, 1F4-1B10).The American Journal of Human Genetics 85, 248–253, August 14, 2009 249
mutations (p.S247P and p.Q300R) located in the highly
conserved AMP binding domain and one missense muta-
tion situated within the C-terminal domain (p.R583H)
(Figure 2B). The functional importance of the AMP-
binding domain, as well as the C-terminal domain, has
previously been demonstrated by base pair substitution
of the FATP1 yeast ortholog, FAT1, and by using protein
domain chimeras of FATP1, FATP4, and FATP6.28,29 These
studies show that the ATP/AMP and FATP/VLACS motifs
are important for transport and activation of fatty acids.
Mutations in the ATP/AMP motif repress both fatty acid
import and fatty acid activation, supporting the notion
that the binding of ATP is required for these functions.
Mutations in the FATP/VLACS motif results in an almost
complete elimination of both transport and activation,
indicating that this region is crucial for FATP function.
Western blot analysis of keratinocyte and ﬁbroblast cell
lines derived from an adult IPS patient and a control indi-
vidual was performed with an antibody detecting the
C-terminal part of FATP4. Cells from the patient homozy-
gous for p.C168X did not show any detectable band
whereas cells from the normal donor revealed a single
band corresponding to the size of FATP4 (Figure 2C). Immu-
nohistochemistry with the same antibody on normal skin
showed a strong expression of FATP4 (Figure 3A), whereas
no staining was detected in a skin biopsy from the IPS
patient (Figure 3B), demonstrating absence of full-length
FATP4.
The fatty acid transport properties as well as the enzy-
matic activity of FATP4 suggest an important role of the
protein for the formation of the skin barrier. To investigate
Figure 3. Analysis of Skin Biopsies
Analysis of skin biopsies from a control (A, C, E) and
an IPS patient homozygous for p.C168X (B, D, F).
(A and B) Immunostaining with a FATP4 antibody
(Abnova) shows strong expression in the normal
epidermis but no expression in the patient spec-
imen.
(C and D) Nile red staining shows an even distribu-
tion of lipids in the control biopsy whereas IPS is
associated with an accumulation of lipids in the
stratum granulosum that coincides with the normal
expression pattern of FATP4 in (A).
(E and F) Staining of neutral lipids with Oil Red O
shows few lipid droplets in normal skin but
numerous droplets in the epidermis of the patient.
for presence of skin lipids in epidermis, we
stained neutral lipids with Nile red. We
observed an equal staining of the epidermal
layers in normal skin (Figure 3C) in contrast
to an intense lipid staining restricted to stratum
corneum (SC) in skin from an adult IPS patient
(Figure 3D). The abnormal distributionof lipids
between epidermal layers in IPS is consistent
with the expressionpattern of FATP4 innormal
epidermis, which seems strongest in the outer
layers (Figure 3A). Epidermal lipid distribution
was also investigated with Oil Red O. Normal epidermis
show few lipid droplets (Figure 3E) when compared to
epidermis of an IPS patient exhibiting numerous small
droplets (Figure 3F). These observations suggest a defect in
lipid homeostasis and skin barrier formation in IPS, which
is similar to that found in the Slc27a4wrfr mice.25
Murine ﬁbroblasts with FATP4 deﬁciency exhibit a
substantial reduction in VLCFA activation, suggesting
that this enzyme is a major VLCFA-CoA synthetase.30 To
investigate the biochemical effects of FATP4 mutations,
we determined LCFA-CoA and VLCFA-CoA synthetase
activity in lysates obtained from ﬁbroblasts homozygous
for the p.C168X mutation. With palmitic acid (C16:0) as
substrate, acyl-CoA formation was identical in wild-type
and mutant cells. In the presence of erucic acid (C22:1),
however, acyl-CoA formation was reduced by 55% in
mutated cells when compared to control cells (wild-type),
suggesting a defect in VLCFA activation (Figure 4A). We
next determined the incorporation of radiolabeled palmitic
acid and erucic acid into neutral and polar lipids of cultured
ﬁbroblasts. As shown in Figures 4A–4D,mutated ﬁbroblasts
show a decreased incorporation of erucic acid into choles-
terol esters (CE), triglycerides (TG), and phospholipids
(PL) by69%,60%, and37%, respectively. The incorporation
of palmitic acid was unchanged in the CE (Figure 4B) and
TG (Figure 4C) fractions and slightly increased (29%) in
the PL fraction (Figure 4D). In contrast to observations in
murine ﬁbroblasts,30 p.C168X ﬁbroblasts did not show
a reduced incorporation of fatty acids into the phosphatity-
lethanolamine (PE) and phosphatidylcholin (PC) fractions.
However, in accordance with this study, we observed250 The American Journal of Human Genetics 85, 248–253, August 14, 2009
Figure 4. Fatty Acid Activation in Fibroblasts from a Control Individual and an IPS Patient Homozygous for p.C168X
(A) Acyl-CoA synthetase activities in lysates of wild-type (ﬁlled bars) and p.C168X (open bars) ﬁbroblasts. Activation of VLCFA and LCFA
were determined with erucic acid (22:1) and palmitic acid (16:0) as substrate, respectively.
(B–D) Incorporation of 3H-labeled erucic acid and palmitic acid (LCFA) into (B) cholesterol esters (CE), (C) triglycerides (TG), and (D)
phospholipids (PL) of wild-type and p.C168X ﬁbroblast. Cells were cultured in the presences of 50 mM radiolabeled fatty acids for
6 hr. Subsequently, lipid fractions were separated by TLC and the comigrating radioactivity was determined by liquid scintillation count-
ing. Data show the mean 5 standard deviation (SD) and are representative for three independent experiments done in triplicate.
p values are generated with two-tailed Student’s t test assuming equal variance.reduced accumulation of radioactivity in the lysophophati-
tylcholin (LPC) fraction (Figure S2). Cellular neutral lipid
accumulation was also investigated with BODIPY 493/503
and FA uptake by C1-BODIPY-C12, a fatty acid analog that
mimics LCFA, respectively. Patient-derived and control ker-
atinocytes show a similar lipid content and uptake of BOD-
IPY (Figure S3). Taken together, our results demonstrate that
FATP4 deﬁciency in human ﬁbroblasts is associated with
reduced VLCFA-CoA synthetase activity and a reduced
incorporation of VLCFA into neutral and polar lipids.
Mice with a disruption of Fatp4 present with a defective
skin barrier function resulting in a severe skin phenotype,
which has been described as restrictive.24 Interestingly,
adult mice can partially compensate for Fatp4 deﬁciency
by other Fatps, and surviving Fatp4-deﬁcient mice present
with a milder phenotype from the age of 10 weeks.31 This
suggests that Fatp4 is critical for the generation of the
epidermal barrier during the embryogenic and neonatal
period but of less importance for its maintenance where
other FATPs may compensate. Similarly, the human IPS
phenotype is severe in the neonatal period but symptoms
become milder with age and are often benign in adults.
Lipid transport and/or processing are pivotal for the skin
barrier function. This is supported by mutations identiﬁed
in different genes encoding proteins of lipid metabolism
downstream of the FATPs in disorders of keratinization.1
Our ﬁndings provide, to our knowledge, the ﬁrst example
of a human inherited disease caused by deﬁciency ofThe Ameria member in the FATP family. These observations empha-
size the critical role of fatty acid metabolism for normal
epidermal barrier function. Exactly how the barrier defect
in IPS might explain massive scaling in utero and prematu-
rity with asphyxia at birth remains to be studied. This also
applies to the intriguing connection between IPS and tran-
sient eosinophilia with atopic manifestations later in life.
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